Target-mediated drug disposition model and its approximations for antibody-drug conjugates

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 41, Issue 1, 2014, Pages 35-47

  Gibiansky, Leonid ^a   Gibiansky, Ekaterina ^a  

^a QuantPharm LLC 49 Flints Grove Drive   (United States)

Author keywords

Antibody drug conjugates; Identifiability of model parameters; Michaelis Menten approximation; Nonlinear pharmacokinetics; Quasi steady state approximation; Target mediated drug disposition

Indexed keywords

ANTIBODIES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; COMPUTER SIMULATION; MAYTANSINE; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; TISSUE DISTRIBUTION;

EID: 84895073197     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-013-9344-y     Document Type: Article

References (11)

1. Mullard Asher (2013) Maturing antibody-drug conjugate pipeline hits 30. Nat Rev Drug Discovery 12:329-332
2. Lin Tibbitts (2012) Pharmacokinetic considerations for antibody drug conjugates. Pharm Res 29:2353-2366
3. Leipold D, Bender B, Xu K, Theil F-P, and Tibbitts J (2009) Understanding the de-conjugation of Trastuzumab-MCC-DM1 through application of a multi-compartmental model of individual drug: antibody species in cynomolgus monkey. Presented at the 2009 American Association for Cancer Research (AACR) Meeting, Denver, Colorado
4. Bender B, Leipold D, Liu L, Xu K, Shen B-Q, Friberg LE, Tibbitts J. A multicompartmental population PK model elucidating the complex disposition of trastuzumab emtansine (T-DM1): an antibody-drug conjugate for the treatment of HER2-positive cancer, Page 21 (2012) Abstr 2607 [ www.page-meeting.org/? abstract=2607 ]
5. Lu D, Joshi A, Wang B, Olsen S, Yi JH, Krop IE, Burris HA, Sandhya Girish S, An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic breast cancer. Clin Pharmacokinet 52(8):657-672
6. Chudasama VL, Schaedeli Stark F, Harrold JM, Tibbitts L, Girish SR, Gupta M, Frey N, Mager DE (2012) Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer. Clin Pharmacol Ther 92(4):520-527. doi: 10.1038/clpt.2012.153
7. Mager DE, Jusko WJ (2001) General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 28:507-532
8. Mager DE, Krzyzanski W (2005) Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res 22(10):1589-1596
9. Gibiansky L, Gibiansky E, Kakkar T, Ma P (2008) Approximations of the target-mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn 35(5):573-591
10. Gibiansky L, Gibiansky E (2009) Target-mediated drug disposition model: approximations, identifiability of model parameters, and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics. Expert Opin Drug Metabol Toxicol 5(7):803-812
11. Yan X, Mager DE, Krzyzanski W (2010) Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models. J Pharmacokinet Pharmacodyn 37(1):25-47